Genome editing is a breakthrough healthcare technology which has the potential to notably change treatment options, largely influence current healthcare models, and impact patients in clinical trials worldwide. The science is advancing rapidly, promising considerable increases in the efficacy and precision of genome editing products with potentially curative treatments for many serious diseases, including thalassaemia and other haemoglobin disorders.
To help move forward the discourse on genome editing and examine how these technologies could become available for patients, the »The future of therapeutic genome editing in European Healthcare Systems » report has been developed following the successful conference on “Conversations on Science, Regulation, and Society”, held in the European Parliament on 25 October 2018 and hosted by Ms María Teresa Giménez Barbat, Member of the European Parliament.
This report brings together the views of representatives from government, industry, patient communities, and civil society, and whilst it does not suggest solutions to the challenges genome editing may face, it spotlights opportunities to encourage continued dialogue among the different stakeholders.
TIF’s Board of Directors Member & Expert Patient, Mr. George Constantinou, has contributed to focus attention on the patients’ experience in the genome editing potential, as far as thalassaemia is concerned.Read the full report